4',7-dihydroxyisoflav-2-ene | 232261-61-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 4',7-dihydroxyisoflav-2-ene
• 英文别名: 4',7-Isoflavandiol；isophenoxodiol；Equol；3-(4-Hydroxy-phenyl)-4H-chromen-7-ol；3-(4-hydroxyphenyl)-4H-chromen-7-ol
• CAS: 232261-61-9
• 化学式: C₁₅H₁₂O₃
• 分子量: 240.258
• InChiKey: QCNUDDPWPNUALZ-UHFFFAOYSA-N

物化性质

• 沸点：
  438.6±45.0 °C(Predicted)
• 密度：
  1.337±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4',7-dihydroxyisoflav-2-ene 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、1.52 MPa 条件下， 反应 10.0h， 以71.9%的产率得到雌马酚
  参考文献：
  名称：

  一种雌马酚的合成方法

  摘要：

  本发明提供一种雌马酚的合成方法，包括以下步骤：以大豆苷元为原料经酯化反应得到化合物B；化合物B经过烯键共轭、羰基的还原反应得到化合物C；化合物C经过脱水反应得到化合物D；化合物D经过双键加氢反应得到雌马酚；本发明合成步骤短、操作简单、经济环保、每步收率在70％以上，总收率有了明显提高，适合工业化大生产。

  公开号：

  CN105777693A
• 作为产物：
  描述：

  大豆甙元 在 硫酸 、 5%-palladium/activated carbon 、 氢气 、 sodium acetate 、 乙酸酐 作用下， 以 甲醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 25.0~62.0 ℃ 、2.53 MPa 条件下， 反应 15.0h， 生成 4',7-dihydroxyisoflav-2-ene
  参考文献：
  名称：

  一种雌马酚的合成方法

  摘要：

  本发明提供一种雌马酚的合成方法，包括以下步骤：以大豆苷元为原料经酯化反应得到化合物B；化合物B经过烯键共轭、羰基的还原反应得到化合物C；化合物C经过脱水反应得到化合物D；化合物D经过双键加氢反应得到雌马酚；本发明合成步骤短、操作简单、经济环保、每步收率在70％以上，总收率有了明显提高，适合工业化大生产。

  公开号：

  CN105777693A

文献信息

• Processes for Preparing Isoflavonoids using 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran as a Starting Material
  申请人：Wang Eng-Chi

  公开号：US20100298581A1

  公开（公告）日：2010-11-25

  Disclosed herein are processes for the preparation of isoflavonoids, in particular haginin E, equol, daidzein, formononetin and the like, in which 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran is used as a common starting material.

  本文披露了一种制备异黄酮类化合物的方法，特别是制备haginin E、equol、daidzein、formononetin等化合物的方法，其中7-苄氧基-3-(4-甲氧基苯基)-2H-1-苯并吡喁被用作共同的起始原料。
• 2-Morpholinoisoflav-3-enes as flexible intermediates in the synthesis of phenoxodiol, isophenoxodiol, equol and analogues: Vasorelaxant properties, estrogen receptor binding and Rho/RhoA kinase pathway inhibition
  作者：Andrew J. Tilley、Shannon D. Zanatta、Cheng Xue Qin、In-Kyeom Kim、Young-Mi Seok、Alastair Stewart、Owen L. Woodman、Spencer J. Williams

  DOI：10.1016/j.bmc.2012.02.008

  日期：2012.4

  isoflavone metabolites, such as the isoflavan equol, contribute to these beneficial effects. In this study we developed a new route to isoflavans and isoflavenes via 2-morpholinoisoflavenes derived from a condensation reaction of phenylacetaldehydes, salicylaldehydes and morpholine. We report the synthesis of the isoflavans equol and deoxygenated analogues, and the isoflavenes 7,4′-dihydroxyisoflav-3-ene (phenoxodiol

  食用异黄酮与心血管疾病的发生率降低相关。流行病学研究和临床数据提供了证据，证明异黄酮代谢物（例如异黄酮雌马酚）有助于这些有益作用。在这项研究中，我们开发了一种新的途径，可通过由苯乙醛，水杨醛和吗啉的缩合反应得到的2-吗啉代异黄酮来制取异黄酮和异黄酮。我们报告了异黄酮雌马酚和脱氧类似物的合成，以及异黄酮7,4'-二羟基异黄酮3-烯（苯氧二酚，haganin E）和7,4'-二羟基异黄酮2-烯（异苯氧二酚）。血管药理学研究表明，所有氧化的异黄酮和异黄酮都可以减弱苯肾上腺素引起的血管收缩，这不受雌激素受体拮抗剂ICI 182,780的影响。此外，2类似物）诱导内皮剥除的大鼠主动脉血管收缩，并减少GTP RhoA的形成，对雌马酚和苯氧二酚的影响最大。对大鼠子宫细胞溶质雌激素受体的配体置换研究表明，该化合物通常是弱结合剂。这些数据与至少部分地通过抑制RhoA / Rho激酶途径而产生的雌马酚和苯氧二
• Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
  申请人：Brinton Diaz Roberta

  公开号：US20080108696A1

  公开（公告）日：2008-05-08

  Select phytoestrogen pharmaceutical compositions and methods of use for promoting neurological health and prevention of age-related neurodegeneration, such as AD, have been developed. These select phytoestrogen formulations are composed of a number of plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The select phytoestrogen formulations are therapeutically useful to both women and men for sustaining neurological health and preventing age-related cognitive decline and neurodegenerative disorders, such as AD. These are administered enterally, transdermally, transmucosally, intranasally or parenterally, in a dosage effective to prevent or alleviate neuronal damage, effect neuronal regeneration or sustain viability, increase expression of anti-apoptotic proteins, and/or decrease indicators of Alzheimer's Disease. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.
• PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF MENOPAUSAL SYMPTOMS
  申请人：Brinton Roberta Diaz

  公开号：US20100113586A1

  公开（公告）日：2010-05-06

  Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and/or post menopause are described herein. These select phytoestrogen formulations are composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The formulations can be administered enterally, transdermally, transmucosally, intranasally or parenterally. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.
• PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF HAIR LOSS
  申请人：Brinton Roberta Diaz

  公开号：US20110091435A1

  公开（公告）日：2011-04-21

  Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with hair loss or prostate cancer/prostate hypertrophy are described herein. These select phytoestrogen formulations are preferably composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in non-reproductive tissues including brain.